Alcohol septal ablation for obstructive hypertrophic cardiomyopathy

Author(s):  
Charles Knight ◽  
Saidi A. Mohiddin

Hypertrophic cardiomyopathy (HCM) is a genetic disease occurring in approximately one in 500–1000 of the general population. HCM is often undiagnosed or misdiagnosed, and asymptomatic cases are often unrecognized. Asymmetric left ventricular (LV) hypertrophy (LVH) most often develops during the period of rapid body growth of adolescence, but it may be present in childhood or, rarely, before birth. Progressive LVH after age 20 is uncommon, but initial diagnosis even in old age is not. The hypertrophy predominantly involves the LV, and is often more marked than in any other cardiac disease. Hypertrophy may involve the right ventricle (RV), and an atrial myopathy may be progressive (left atrial enlargement [LA) and increased risks of atrial fibrillation [AF]). RV and LA involvement may be secondary to the LV disease, and/or a primary consequence of the basic molecular defect. The LVH represents hypertrophy and hyperplasia of several cell types, including cardiac myocytes, fibroblasts, and smooth muscle cells, along with excessive collagen and matrix deposition, and abnormalities of the microvasculature. The normal parallel arrangement of myocytes is often disturbed (fibre disarray). Clinical practice addresses three needs: 1) assessing and treating the symptomatic patient; 2) assessing and addressing prognostic risks; and 3) genetic counselling, family screening, and mutation detection (genetic testing). Symptoms due to HCM will often have a striking variation in severity when patients may describe good and bad days, exacerbation of symptoms following large meals and an intolerance of dehydration or a hot climate. Chest pain, with a quality similar to angina pectoris but often developing at rest, dyspnoea, palpitations, dizziness, pre/syncope, and fatigue are the common complaints. Although the relief of LV outflow obstruction (LVOTO) by alcohol septal ablation (ASA) for the management of symptomatic HCM is the focus of this chapter, we will first describe some of the more important features of HCM in order that this procedure can be placed in the context of a complex cardiac condition.

Author(s):  
Charles Knight ◽  
Saidi Mohiddin ◽  
Constantinos O’Mahony

Hypertrophic cardiomyopathy (HCM) is a genetic disease occurring in up to 1 in 500 of the general population. HCM is often undiagnosed or misdiagnosed, and asymptomatic cases are often unrecognized. Asymmetric left ventricular hypertrophy (LVH) most often develops during the period of rapid body growth of adolescence, but it may be present in childhood or even before birth. Progressive LVH after age 20 is uncommon, but initial diagnosis even in old age is not. The hypertrophy predominantly involves the left ventricle, and is often more marked than in any other cardiac disease. Hypertrophy may involve the right ventricle, and an atrial myopathy may be progressive (left atrial enlargement and increased risks of atrial fibrillation). Right ventricle and left atrium involvement may be secondary to the left ventricular disease and/or a primary consequence of the basic molecular defect. The LVH represents hypertrophy and hyperplasia of several cell types, including cardiac myocytes, fibroblasts, and smooth muscle cells, along with excessive collagen and matrix deposition, and abnormalities of the microvasculature. The normal parallel arrangement of myocytes is often disturbed (fibre disarray).


2018 ◽  
Vol 2018 (3) ◽  
Author(s):  
Juan José Santos Mateo ◽  
Juan R Gimeno

Alcohol septal ablation (ASA) has become an alternative to surgical myectomy in obstructive hypertrophic cardiomyopathy since it was first introduced in 1994 by Sigwart. The procedure alleviates symptoms by producing a limited infarction of the upper interventricular septum, resulting in a decrease in left ventricular outflow tract (LVOT) gradient. The technique has been improved over time and the results are comparable with those of myectomy. Initial concerns about long-term outcomes have been largely resolved. In this review, we discuss indications, technical aspects, clinical results and patient selection to ASA.


2021 ◽  
Vol 25 (2) ◽  
pp. 108
Author(s):  
С. А. Будагаев ◽  
А. В. Афанасьев ◽  
А. В. Богачев-Прокофьев ◽  
А. С. Залесов ◽  
М. А. Овчаров

<p>On 22 December 2020, <em>Circulation</em> published the new American College of Cardiology / American Heart Association guidelines for the diagnosis and treatment of patients with hypertrophic cardiomyopathy. The most important guidelines were those concerning pharmacological and invasive methods of treating symptomatic patients with obstruction of the left ventricular outlet. Considering the most recent clinical studies, the indications for invasive methods of treatment have expanded to include septal myectomy and alcohol septal ablation. A separate section in the guidelines has been devoted to the management of non-obstructive hypertrophic cardiomyopathy with preserved left ventricular ejection fraction. The recommendations for patients with hypertrophic cardiomyopathy with atrial fibrillation, ventricular arrhythmias and severe heart failure have been revised.</p><p>Received 26 March 2021. Revised 12 May 2021. Accepted 13 May 2021.</p><p><strong>Funding:</strong> The study did not have sponsorship.</p><p><strong>Conflict of interest:</strong> Authors declare no conflict of interest.</p><p><strong>Author contributions</strong><br />Conception and study design: S.A. Budagaev, A.V. Afanasyev, A.V. Bogachev-Prokophiev<br />Data collection and analysis: S.A. Budagaev, M.A. Ovcharov<br />Drafting the article: S.A. Budagaev, A.V. Afanasyev, A.S. Zalesov<br />Critical revision of the article: A.V. Bogachev-Prokophiev<br />Final approval of the version to be published: S.A. Budagaev, A.V. Afanasyev, A.V. Bogachev-Prokophiev, A.S. Zalesov, <br />M.A. Ovcharov</p>


Sign in / Sign up

Export Citation Format

Share Document